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Background: Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-
pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-
administered to cancer patients as part of a DC-based vaccine, are being widely tested in the clinical setting.
However, endogenous DCs in tumor-bearing individuals are often dysfunctional, suggesting that ex vivo educated
DCs might be superior inducers of anti-tumor immune responses. We have previously shown that prothymosin
alpha (proTα) and its immunoreactive decapeptide proTα(100–109) induce the maturation of human DCs in vitro.
The aim of this study was to investigate whether proTα- or proTα(100–109)-matured DCs are functionally
competent and to provide preliminary evidence for the mode of action of these agents.
Results: Monocyte-derived DCs matured in vitro with proTα or proTα(100–109) express co-stimulatory molecules
and secrete pro-inflammatory cytokines. ProTα- and proTα(100–109)-matured DCs pulsed with HER-2/neu peptides
induce TH1-type immune responses, prime autologous naïve CD8-positive (+) T cells to lyse targets expressing the
HER-2/neu epitopes and to express a polyfunctional profile, and stimulate CD4+ T cell proliferation in an HER-2/neu
peptide-dependent manner. DC maturation induced by proTα and proTα(100–109) is likely mediated via TLR-4, as
shown by assessing TLR-4 surface expression and the levels of the intracellular adaptor molecules TIRAP, MyD88
and TRIF.
Conclusions: Our results suggest that proTα and proTα(100–109) induce both the maturation and the T cell
stimulatory capacity of DCs. Although further studies are needed, evidence for a possible proTα and proTα(100–109)
interaction with TLR-4 is provided. The initial hypothesis that proTα and the proTα-derived immunoactive decapeptide
act as “alarmins”, provides a rationale for their eventual use as adjuvants in DC-based anti-cancer immunotherapy.
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Anti-cancer vaccines are designed to break tolerance to
self and stimulate strong and durable anti-tumor im-
munity. Administering defined tumor-derived epitopes
to cancer patients for the activation of helper and cyto-
toxic T cells has been shown to enhance anti-cancer im-
mune responses in vivo and in some cases to lead to* Correspondence: rtsitsil@biol.uoa.gr
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reproduction in any medium, provided the orobjective clinical responses [1-3]. To optimize the
efficacy of peptide-based anti-cancer vaccines, combina-
torial approaches stimulating both innate and adaptive
immunity are now being clinically evaluated [4,5].
Mature dendritic cells (DCs) are key players for eliciting
such responses, as they present antigens to T cells and
provide the necessary co-stimulatory signals and cyto-
kines favoring the efficient activation of tumor-reactive
immune cells [6,7]. DC maturation can be induced
in vivo upon admixing and co-administering immuno-
genic peptides with adjuvants, but to date this strategyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2172/14/43has been proven successful only when vaccinating against
common pathogens [8]. In cancer patients, the presence
of tumor-associated suppressive factors impairs endogen-
ous DC functions [9], a condition that can be bypassed
only by the adoptive transfer of ex vivo matured immuno-
competent DCs [10,11].
Adjuvants comprise, among others, Toll-like receptor
(TLR) agonists, the majority of which reportedly promotes
DC maturation [12]. A subcategory thereof are molecules
with so-called pathogen-associated molecular patterns
(PAMPs), such as CpG oligodeoxynucleotides that signal
through TLR-9 [13], poly-I:C ligating TLR-3 [14],
imiquimod, a TLR-7 agonist [15] and monophosphoryl
lipid A, a TLR-4 agonist [16]. A second group consists of
molecules possessing damage-associated molecular pat-
terns (DAMPs) or “alarmins”. High mobility group box 1
(HMGB1) protein and heat shock protein (HSP) 90 are
notable examples of DAMPs. Both proteins are strictly
intracellular under normal physiological conditions, but
when excreted eg. from damaged cells, signal through
TLR-4, sensitize DCs and promote adaptive immune re-
sponses [17]. This functional dualism, in and out of the
cell, also characterizes prothymosin alpha (proTα).
In normal living cells, proTα is localized in the nucleus
where it controls the cell cycle and promotes cell prolif-
eration. Released from dead cells, extracellular proTα ac-
quires multi-functional immunomodulatory properties
[18]. We and others have previously shown that proTα
upregulates the expression of IRAK-4 in human mono-
cytes [19], ligates TLR-4 on murine macrophages and
signals through MyD88-dependent and independent path-
ways [20]. Similar to its immunoreactive decapeptide
proTα(100–109) [21], it upregulates the expression of
HLA-DR [22], CD80, CD83 and CD86 and promotes mat-
uration of human DCs in vitro [23].
Here, we show that DCs matured ex vivo in the presence
of proTα or proTα(100–109) are not only phenotypically
but also functionally competent, secrete pro-inflammatory
cytokines and induce TH1-type immune responses in the
presence of tumor-associated immunogenic epitopes of
the oncoprotein HER-2/neu. DCs matured with proTα or
proTα(100–109) prime naïve CD8-positive (+) T cells to
exert HER-2/neu peptide-specific cytotoxicity and CD4+
T cells to proliferate in a peptide-dependent manner.
Finally, we provide preliminary evidence suggesting that
both proTα and its decapeptide proTα(100–109) likely
signal viaTLR-4 in human DCs.
Results
Phenotype of and cytokine production by proTα- or
proTα(100–109)-matured DCs
We have previously shown that proTα and proTα(100–109)
efficiently mature human DCs in vitro, as indicated by
the induction of surface expression of established DC-markers to levels comparable to those induced by
lipopolysacharide (LPS) [23] or tumor necrosis factor
(TNF)-α (this report). As shown in Figure 1, LPS-
matured DCs significantly upregulated the expression
of HLA-DR, CD11b, CD80, CD83, CD86 and CD40, to
levels comparable to TNF-α-matured DCs (p < 0.001
compared to iDCs for all values). Similarly, both agents
caused a reduction of CD14 expression. In agreement
with our previous study [23], iDCs matured with either
proTα or its decapeptide presented a similar phenotype
to LPS- or TNF-α-matured DCs, upregulating the ex-
pression of all co-stimulatory molecules (p < 0.05-0.001,
compared to iDCs; Figure 1) and downregulating CD14
(p < 0.01, compared to iDCs).
In conjunction with their phenotype, functionally com-
petent mature DCs secrete pro- and anti-inflammatory
cytokines [6]. Therefore, we assessed the production of
TNF-α, interleukin (IL)-12 and IL-10 from iDCs and
mature DCs and determined the IL-12:IL-10 ratio. We
present these data because high TNF-α levels, as well as
a balance between IL-12:IL-10 in favor of IL-12 have
been proposed to promote TH1-polarization [24]. As
shown in Figure 2, iDCs produced low amounts of all
three cytokines, whereas mature DC supernatants col-
lected 48 h after addition of LPS or TNF-α were rich in
TNF-α and IL-12. Compared to iDCs, higher TNF-α
and IL-12 levels were also found in supernatants of cul-
tures of DCs matured with proTα and proTα(100–109).
Although the absolute concentrations of cytokines varied
among the differentially matured DCs, their overall
cytokine-production patterns were comparable. Most
importantly, the mean IL-12:IL-10 ratios were similar
(6.61, 6.45, 7.89 and 5.18, for LPS-, TNF-α-, proTα- and
proTα(100–109)-matured DCs, respectively). These data
suggest that the peptides bias immunoreactivity towards
a pro-inflammatory TH1-type of response.
Finally, in the presence of a blocking antibody against
TLR-4 (a-TLR-4; Figure 2), lower amounts of cytokines
were secreted by LPS-, proTα- and proTα(100–109)-
matured DCs, but not TNF-α-matured DCs. Notably,
a-TLR-4 reduced the levels of LPS- and proTα-induced
IL-12 production by 55 and 47%, respectively (p < 0.05),
implying that IL-12 production by LPS- and proTα-
matured DCs is at least partially, TLR-4-dependent [25].ProTα and proTα(100–109) lead to TH1-polarized tumor
peptide-reactive immune response
As optimally matured DCs prime antigen-specific CD4+
and CD8+ T cell activation and proliferation of naive
T cells [7], we next assessed whether proTα- and
proTα(100–109)-matured DCs are functionally compe-
tent, i.e., induce in vitro the selective expansion of tumor
antigen-specific T cells.
Figure 1 ProTα or proTα(100–109) induce DC maturation. Monocytes were differentiated to immature DCs (iDCs) upon 5-day incubation with
GM-CSF and IL-4, followed by 48 h exposure to LPS, TNF-α, proTα or proTα(100–109). Expression of surface HLA-DR, CD11b, CD80, CD83, CD86, CD40
and CD14 on iDCs and mature DCs are shown as mean fluorescence intensity (MFI) ± SD from 5 donors. * p < 0.05; ** p < 0.01; *** p < 0.001, compared
to iDCs.
Figure 2 ProTα- or proTα(100–109)-matured DCs secrete pro-inflammatory cytokines. Culture supernatants from iDCs and DCs matured
with LPS, TNF-α, proTα or proTα(100–109) for 48 h were assessed for their TNF-α, IL-12 and IL-10 content. iDCs were treated (+) or not (−) with an
anti-TLR-4 mAb (a-TLR-4) for 1 h prior to their maturation. Data are given as mean values ± SDs from 3 donors. * p < 0.05.
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proTα(100–109) or TNF-α (used as a conventional DC
maturation agent) were pulsed with the HLA-A2 and
HLA-DR4-restricted HER-2/neu(369–377) [HER-2(9369)]
and HER-2/neu(776–790) [HER-2(15776)] epitopes, and
used to prime autologous naïve T cells isolated from the
peripheral blood of HLA-A2+/DR4+ healthy donors.
T cells were restimulated twice, at weekly intervals, with
similarly matured autologous DCs. Twelve hours after the
third stimulation their production of TNF-α, interferon
(IFN)-γ, IL-2, IL-4, IL-10 and IL-17 was analysed. Figure 3
shows the percentages of IFN-γ+, IL-2+, IL-4+ and IL-10+
CD4+ T cells from one representative donor of 5 tested
with similar results (Additional file 1: Table S1A). In the
presence of unpulsed TNF-α-matured DCs, only a low
percentage of CD4+ T cells produced IFN-γ (0.02%),
which was significantly increased (23.30%) in the presence
of the HER-2/neu peptides. An analogous increase in the
percentage of IFN-γ-producing cells was also recorded in
CD4+ T cells stimulated with proTα- or proTα(100–109)-
matured DCs in the presence of the same peptides
(21.78% and 22.93%, respectively, compared to 0.01% and
0.02% in the absence of HER-2/neu peptides; Figure 3).
The percentages of IL-2-producing CD4+ T cells in all
groups were also significantly enhanced upon stimulation
with HER-2/neu peptide-pulsed DCs (35.02% for TNF-α-,























Figure 3 T cells stimulated with proTα- or proTα(100–109)-matured H
cytokines. Monocytes from HLA-A2+/DR4+ donors were differentiated to
with HER-2(9369) and HER-2(15776) epitopes and used to stimulate autologo
production of IFN-γ, IL-2, IL-4 and ΙL-10, in the absence (−) or presence (+)
row, DCs matured with proTα; bottom row, DCs matured with proTα (100–
on gated CD4+ T cells. Shown data are from one representative donor of 5matured DCs, compared to 0.08%, 0.09% and 0.71% of the
respective unpulsed groups; Figure 3). A similar en-
hancement was also seen for TNF-α-producing CD4+
T cells (Additional file 1: Table S1A). In contrast,
production of IL-4 and IL-10 was only marginally in-
creased when CD4+ T cells were stimulated with HER-
2/neu peptide-pulsed DCs, regardless of the factor used
for DC maturation (Figure 3). Specifically, the percent-
age of CD4+ T cells producing IL-4 was increased from
0.01% (without peptides) to 1.17% among T cells stimu-
lated with peptide-pulsed TNF-α-matured DCs, from
0.01% to 0.61% in the proΤα- and from 0.02% to 0.82%
in the proTα(100–109)-matured DC groups. A minor
enhancement was also recorded for IL-10 production;
IL-10+ cells increased from 0.03% to 0.11% in the TNF-α-,
from 0.01% to 0.02% in the proΤα- and from 0.01% to
0.02% in the proTα(100–109)-matured DC cultures with-
out and with HER-2/neu peptides, respectively. IL-17 pro-
duction exhibited a similar pattern of marginal increase in
CD4+ T cells stimulated in the presence of all matured
antigen-pulsed DCs (Additional file 1: Table S1A). These
data suggest that proTα- and proTα(100–109)-matured
DCs are immunocompetent and in the presence of spe-
cific tumor antigenic epitopes, favor the in vitro produc-
tion of pro-inflammatory (IFN-γ, IL-2, TNF-α), rather
than anti-inflammatory cytokines (IL-4, IL-10) and IL-17













ER-2/neu-peptide-pulsed autologous DCs produce TH1-type
iDCs, matured for 48 h with TNF-α, proTα or proTα(100–109), pulsed
us T cells. Recovered CD4+ T cells were analyzed for intracellular
of the HER-2/neu peptides. First row, DCs matured with TNF-α; middle
109). Numbers indicate percentage of positive cells for each cytokine
tested.
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peptide-specific CD8+ T cell responses
Cell-mediated immunity requires initial collaboration
between TH1 CD4+ and CD8+ T cells [26]. Thus, we





















Figure 4 T cells stimulated with proTα- or proTα(100–109)-matured D
production of TNF-α (left) and surface expression of CD107a (right) in CD8+
proTα (middle row) or proTα(100–109) (bottom row), in the absence (−) or
percentages of positive cells on gated CD8+ T cells. Shown are data from o
with TNF-α-, proTα- or proTα(100–109)-matured DCs, were used as effector
Where indicated, mAb to MHC class I molecules was added throughout th
T ratio was 10:1. Data represent mean % cytotoxicity ± SD from 2–5 donorsmatured DCs can elicit tumor peptide-specific cytotoxic
T cell immune responses.
CD8+ T cells recovered from the same stimulation
cultures as aforementioned were assessed for the intra-










Cs are cytotoxic in the presence of HER-2(9369). (A) Intracellular
T cells stimulated with DCs matured for 48 h with TNF-α (first row),
presence (+) of the HER-2/neu peptides. Numbers indicate
ne representative experiment of 5 performed. (B) T cells stimulated
s (E) against unloaded, HER-2(9369)- and tyr(9369)-loaded T2 targets (T).
e culture period at a final concentration of 5 μg/mL. In all assays the E:
.
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kine production in the presence of HER-2/neu peptides
as did CD4+ T cells. The percentage of TNF-α+ cells
was increased from 0.35% (unpulsed) to 47.52% (pulsed)
when T cells were stimulated with TNF-α-matured DCs,
and from 0.12% to 45.38% for proTα- and from 0.13% to
42.88% for proTα(100–109)-matured DCs (Figure 4A).
In addition and in accordance with the results recorded
for CD4+ T cells, IL-2- and IFN-γ-producing CD8+ T cells
were also increased in the presence of peptide-pulsed
DCs in the cultures, whereas differences in the percent-
ages of IL-10-producing CD8+ T cells were only mar-
ginal (Additional file 1: Table S1A).
The same cells were assessed for the expression of
CD107a, as a surrogate marker for cytotoxicity [27]. In
the absence of HER-2(9369), a low percentage of CD8+
T cells stimulated with TNF-α-matured DCs expressed
CD107a (3.70%; Figure 4A), which increased when cells
were stimulated with HER-2(9369)-pulsed DCs (54.75%).
Similar CD107a upregulation was observed in CD8+
T cells stimulated with proTα- and proTα(100–109)-
matured HER-2(9369)-pulsed DCs (36.86% and 41.99%,
respectively, compared to 2.80% and 2.17% of the
unpulsed groups; Figure 4A). Since TNF-α mediates target
cell damage and CD107a-expressing CD8+ T cells are
cytotoxic [27], our results suggest that proTα- and
proTα(100–109)-matured DCs efficiently activate CD8+
cytotoxic T cells, which were able to kill targets presenting
the immunogenic epitope versus which they were primed.
Cytotoxic activity was verified by using 51Cr-labeled
HLA-A2+ T2 cells loaded with HER-2(9369) or an irrele-
vant epitope, tyrosinase(369–377) [tyr(9369)]. CD8+ T cells
thrice stimulated with peptide-pulsed TNF-α-, proTα- or

















Figure 5 HER-2(9369)-specific T cells, stimulated with proTα- or proTα
producing IFN-γ, TNF-α, IL-2 or CD107a was determined in total responsive
with TNF-α, proTα or proTα(100–109). Mean ± SE of data obtained from 3 dthese peptide-loaded T2 targets. The results showed that
CD8+ T cell mean cytotoxicity against non-peptide loaded
T2 targets did not exceed 30% in any group (26.9% for
TNF-α, 23.7% for proTα- and 21.4% for proTα(100–109)-
matured DCs; Figure 4B), whereas HER-2(9369)-loaded T2
targets were lysed twice as efficiently by CD8+ T cells re-
covered from all stimulation cultures (49.9% for TNF-α-,
46.6% for proTα- and 40.4% for proTα(100–109)-matured
DCs; Figure 4B). Cytotoxicity against T2 targets loaded
with tyr(9369) was low and in no instance exceeded 30%.
These cytotoxic responses were significantly decreased by
monoclonal antibody (mAb) to MHC class I molecules,
suggesting that the CD8+ T cells generated by our stimu-
lation protocol are MHC class I-restricted and HER-2
(9369)-specific (Figure 4B).
Polyfunctionality of HER-2(9369)–specific CD8+ T cells
Based on previous studies associating T cell polyfunctionality
with high IFN-γ production and the quality of the elic-
ited responses [28,29], we carried out a functional ana-
lysis of the HER-2(9369)-specific CD8+ T cells
generated in these experiments. Using FlowJo software,
we analyzed their ability to produce effector cytokines
(IFN-γ, TNF-α and IL-2) and to degranulate (expression
of CD107a). Quantifying the fraction of the responsive
CD8+ T cells producing any one (1+), any two (2+), any
three (3+) or all four (4+) mediators, we observed that ap-
proximately a mean ~16% of the responsive CD8+ T cells
were 2+ cells, regardless of the agent used to mature the
DCs that stimulated them (16.26% for TNF-α; 16.92%
for proTα; 15.95% for proTα(100–109); Figure 5). In all
experimental groups, 3+ cells were also detected in in-
creased percentages (8.13% for TNF-α; 7.03% for proTα;





(100–109)-matured DCs, are polyfunctional. The proportion of cells
CD8+ T cells recovered from cultures stimulated with DCs matured
ifferent donors are shown.
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data suggest that proTα- or proTα(100–109)-matured
DCs were able to induce polyfunctional (2+, 3+) CD8+
peptide-specific T cell responses at least as well as
TNF-α-matured DCs.
T cells stimulated with proTα- or proTα(100–109)-matured
DCs proliferate in response to the HER-2(15776) epitope
T cell proliferation was assessed by the incorporation of
3H-thymidine. HER-2(15776)-sensitized T cells coincubated
with HER-2(15776)-, tyrosinase(448–462) [tyr(15448)]-pulsed
or unpulsed DCs, specifically proliferated in response
only to the HER-2/neu epitope (Table 1). ProTα- and
proTα(100–109)-matured DCs showed relatively high
mean stimulation indices (S.Is) (2.64 and 2.26, respect-
ively), comparable to those recorded for TNF-α-matured
DCs (3.09). Addition of mAb to MHC class II molecules
reduced mean S.Is in all groups (0.87 for TNF-α; 0.93 for
proTα; 0.98 for proTα(100–109)). These results suggest
that following our in vitro culture protocol, peptide-
reactive T cells are generated, which proliferate only in a
HER-2(15776)-dependent MHC class II-restricted manner.
ProTα and proTα(100–109) induce the maturation of DCs
via triggering TLR-4
We have previously reported that stimulation of human
monocytes with proTα upregulated IRAK-4, a protein
kinase involved in TLR downstream signaling [19],
whereas Mosoian et al. [20] showed that proTα ligates
TLR-4 and signals through both TRIF- and MyD88-
dependent pathways. To determine whether TLR-4 is
triggered by our peptides, we studied the kinetics of TLR-
4 surface expression on proTα and proTα(100–109)-
stimulated DCs. Immature DCs (iDCs) and DCs maturedTable 1 T cells stimulated with proTα- or proTα(100–109)-ma
pulsed DCs












HER-2(15776) + anti-MHC class II
* Mean cpm, S.I. ± SD from 2–5 donors.with LPS (a known TLR-4 ligand; [30]), proTα or
proTα(100–109) for 15 min, 30 min, 1 h, 18 h and 36 h
were analyzed by flow cytometry. The percentage of sur-
face TLR-4 expression over time is presented in Figure 6.
Maturation of DCs with LPS led to an early (15 and
30 min) decrease of TLR-4 expression (by ~15%) due to
internalization [31], and a subsequent increase from 1 to
18 h [32]. At 36 h post-LPS addition, TLR-4 expression was
lower and comparable to that of iDCs (0 h). ProTα and
proTα(100–109), marginally downregulated TLR-4 expres-
sion at 30 min and, similarly to LPS, transiently increased it
from 1 to 18 h. As with LPS-matured DCs, basal levels of
TLR-4 expression were detected at 36 h post-maturation.
The similar kinetics of TLR-4 expression in LPS-, proTα-
and proTα(100–109)-matured DCs is consistent with the
notion that the two peptides interact with TLR-4.
To extend these findings, we next investigated the
intracellular expression levels of three adaptor molecules
that participate in signaling pathways downstream of
TLR-4, namely TRIF, an adaptor molecule common to
TLR-3 and -4 signaling; TIRAP, a signaling adaptor com-
mon to TLR-2, and -4; and MyD88, a molecule
upregulated upon ligation of all TLRs except TLR-3 [33].
We specifically selected these three adaptors because this
constellation is unique to TLR-4 activation. Total cell ex-
tracts from iDCs and DCs matured with LPS, proTα or
proTα(100–109) for 1 h and 18 h were immunoblotted
(Figure 7A). Upon densitometric quantification of each
protein band detected, expression relative to GAPDH was
calculated. As shown in Figure 7B, addition of LPS led to
a significant ~2-3 fold increase of the expression of all
three adaptors within 1 h (3.05 for TRIF, 2.88 for TIRAP
and 1.81 for MyD88) relative to iDCs (1.38 for TRIF, 1.00
for TIRAP and 0.74 for MyD88). At 18 h post-addition oftured DCs proliferate in the presence of HER-2(15776)-




13693 ± 1413 1
42314 ± 7139 3.09 ± 0.52
16433 ± 1840 1.20 ± 0.13
11914 ± 2033 0.87 ± 0.15
13145 ± 1742 1
34702 ± 5143 2.64 ± 0.39
17220 ± 2974 1.31 ± 0.23
12225 ± 2603 0.93 ± 0.20
14577 ± 1041 1
32944 ± 6567 2.26 ± 0.45
15306 ± 3608 1.05 ± 0.25
14285 ± 2989 0.98 ± 0.20
Figure 6 Expression of TLR-4 on DCs matured with LPS, proTα or proΤα(100–109). iDCs differentiated from human monocytes (0 h) were
matured with LPS, proΤα and proΤα(100–109) for 15 min, 30 min, 1 h, 18 h and 36 h, and analyzed for TLR-4 surface expression. Data show mean
TLR-4 surface expression ± SD from 3 donors.
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comparable to iDCs (1.35 for TRIF, 1.16 for TIRAP and
1.20 for MyD88). A similar trend of increased expression
was also observed 1 h after addition of proTα (2.537 for
TRIF, 2.28 for TIRAP and 1.577 for MyD88) or
proTα(100–109) (1.62 for TRIF, 1.423 for TIRAP, 1.06 for
MyD88), although in the latter case, the detected protein
levels were lower. As with LPS, 18 h after proTα or
proTα(100–109) DC-stimulation, the expression of TRIF,
TIRAP and MyD88 was reduced and was similar to iDCs.
These data, in conjunction with the cytokine profile
shown in Figure 2, suggest that LPS, proTα, and possibly
also proTα(100–109), activate DCs at least partly through
one common TLR-4-dependent intracellular signaling
pathway.
Discussion
We have previously shown that human monocyte-
derived iDCs activated in vitro with proTα or its immu-
noreactive decapeptide, proTα(100–109), acquire a
mature DC phenotype [23]. Here, we show that DC mat-
uration induced by proTα or proTα(100–109) promotes
the secretion of IL-12, rather than IL-10, from these
cells. Thus, both proTα- and proTα(100–109)-matured
DCs possess immunostimulatory properties appropriatefor the efficient activation of T cells, through their en-
hanced antigen-presenting capacity (HLA-DR; signal 1),
the increased expression of co-stimulatory molecules
(CD80/CD86; signal 2) and the secretion of inflamma-
tory mediators (IL-12), recently proposed to act as signal
3 for optimizing effector T cell functions [34,35].
We assessed whether these ex vivo generated DCs can
present tumor-associated immunogenic peptides to au-
tologous T cells, along with the appropriate signals for
their activation. We pulsed DCs with one MHC class I-
and one class II-restricted immunodominant epitope
from the oncoprotein HER-2/neu, HER-2(9369) and
HER-2/neu(15776), respectively [36,37]. Our results show
that proTα- or proTα(100–109)-matured HER-2/neu
peptide-pulsed DCs favor the generation of TH1-type
immune responses in vitro, by polarizing CD4+ T cells
to produce pro-inflammatory cytokines. This cytokine
milieu, characterized by high levels of IFN-γ and IL-2,
results in the generation of strong CD8+ T cell
responses [26,38], as we also observed. Indeed, CD8+
effectors recovered from the same stimulation cultures
exhibited a pro-inflammatory cytokine profile similar to
the CD4+ T cells (Additional file 1: Tables S1A and B) and
enhanced HER-2(9369)-specific MHC class I-restricted























Figure 7 Increased TLR-4-associated adaptor molecule expression in human DCs matured with proTα or proTα(100–109). (A) Representative
immunoblots of TRIF, TIRAP and MyD88 expression in cell extracts of iDCs and DCs matured with LPS, proTα or proTα(100–109) for 1 h and 18 h.
GAPDH was used to verify equal loading. (B) Densitometry analysis of the adaptor proteins TRIF, TIRAP and MyD88, expressed as relative (%)
expression versus GAPDH. Mean values of 4 independent experiments ± SD are shown. * p < 0.05; ** p < 0.01; *** p < 0.001.
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tures were polyfunctional, a quality reportedly associated
with superior T cell performance [28,29,39]. These find-
ings, in conjunction with the observed enhancement of
HER-2(15776)-specific T cell proliferation, suggest that in
the presence of tumor antigenic peptides, proTα- and
proTα(100–109)-matured DCs efficiently promote the ex-
pansion of peptide-specific T cells.
Different DC-stimulating agents, including TLR li-
gands, have long been and still are being explored to
optimize the immunostimulatory properties of DCs
[10,11,40,41]. Although it was initially proposed that
TLRs recognized only PAMPs, accumulating evidence to
date suggests that TLRs also bind and respond to en-
dogenous ligands released during tissue injury and in-
flammation, termed DAMPs or “alarmins” [42]. Mostprominent among the alarmins are HMGB1, members
of the HSP family and granulysin [43], all of which ma-
ture and activate DCs in vitro and bias immune re-
sponses towards a TH1-type, when used as vaccine
adjuvants in vivo [44-48]. We and others have previously
shown that proTα promotes antigen-specific adaptive
immune responses [20,49-52] and based on the data
presented herein, we now identify proTα as an alarmin.
Moreover, in line with data on immunoreactive peptide-
fragments derived from either HMGB1 (Hp91; [53])
or HSP70 (HSP70359-610; [46]), we show that the im-
munologically active site of proTα, the decapeptide
proTα(100–109) [23], also favors TH1-polarization and
induces HER-2/neu peptide-specific immune responses.
To suggest a possible molecular mechanism under-
lying the effect of proTα and proTα(100–109), and
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we investigated whether TLR-4 expressed on human ma-
ture DCs is triggered by proTα or proTα(100–109). Our
results show that proTα- or proTα(100–109)-induced DC
maturation was associated with modulation of TLR-4
surface expression. Moreover, the expression of three
TLR-4-associated intracellular adaptors, TRIF, TIRAP and
MyD88, was promptly (at 1 h post-stimulation) increased
in proTα- or proTα(100–109)-matured DCs, providing in-
direct evidence that the adjuvant activity of proTα and
proTα(100–109) most likely involves TLR-4. Our data are
in agreement with those of Mosoian et al. [20], showing
that in murine macrophages proTα signals through the
MyD88- and the TRIF-dependent pathways inducing
TNF-α and type I IFN production, respectively. TLR
ligation is a common mechanism of action, shared by dif-
ferent DAMPs. TLR-2 and -4 are involved in HMGB1 sig-
naling in vitro [54-56], and several HSPs, including
HSP22, HSP60, HSP70 and HSP90 also act as TLR-4 ago-
nists [17,57-59]. Our results add to these observations,
suggesting that both proTα and its shorter immunoactive
decapeptide likely signal through TLR-4. The ambiguities
raised as to whether proTα and proTα(100–109) share a
common mechanism of action on DCs with LPS, could be
attributed to: (1) inadequate internalization of TLR-4 by
monocyte-derived human DCs, which reportedly are
CD14low (Figure 1, Additional file 2: Figure S1; [60,61]).
Indeed, stimulation of CD14high human monocytes and
monocyte-derived human macrophages (Additional file 3:
Figure S2) with proTα or proTα(100–109), induced the
rapid CD14-dependent endocytosis of TLR-4, with kin-
etics similar to the response to LPS (Additional file 2:
Figure S1); (2) differential requirements for TLR-4-medi-
ated signaling depending on the cell population (eg.
monocytes, macrophages versus DCs; [62]) and/or cell ori-
gin (eg. mouse versus human; [63]); and (3) the involve-
ment of other TLRs (eg. TLR-2) and/or PRRs in proTα-
and proTα(100–109)-induced DC signaling. In support of
the latter, a similar phenomenon has been described for
HMGB1; the intact protein signals through TLR-2 and -4
[53], and its immunostimulatory peptide Hp91 acts via
TLR-3 or even other receptors [45].Conclusion
Taken altogether, we show herein that proTα and
proTα(100–109) optimize immunogenic peptide-pulsed
DC functionalities in vitro, possibly by TLR-4 triggering.
Ex vivo education of DCs by proTα or proTα(100–109)
results in their polarization to type-1 DCs, with increased
capacity to stimulate tumor peptide-specific T cell re-
sponses and to render cytotoxic T cells polyfunctional. If
this holds true also in vivo, then these molecules could be
promising components of DC-based anti-cancer vaccines.Methods
Peptide synthesis
ProTα(100–109), and the tumor antigen epitopes HER-2
(9369), tyr(9369) (HLA-A2-restricted) [64], HER-2(15776)
and tyr(15448) (HLA-DR4-restricted) [36,64] were syn-
thesized by the Fmoc (9-fluorenylmethoxycarbonyl)/tBu
chemistry utilizing a multiple peptide synthesizer Syro II
(MultiSynTech, Witten, Germany). Crude peptides were
purified by HPLC on a reverse phase C18 Nucleosil
100-5C column (HPLC Technologies, UK) to a purity of
>95%, using a linear gradient of 5.8% acetonitrile in 0.05%
trifluoroacetic acid for 45 min. All peptides were charac-
terized by matrix-assisted laser desorption ionization-time
of flight mass spectrometry and results were in all cases in
agreement with the calculated masses. Human recombin-
ant proTα was purchased from Alexis Biochemicals, CA,
USA and passed through an Endotoxin removal column
(Pierce Biotechnology). Prior to their use, all peptides and
proTα were tested for endotoxin levels using the LAL
chromogenic Endotoxin Quantitation kit (Pierce Biotech-
nology, IL, USA) according to the manufacturer’s instruc-
tions. They were endotoxin-free.
Cell lines and PBMC isolation
Human T2 cells (HLA-A*0201) were cultured in RPMI
1640, supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 2 mM L-glutamine, 10 mM Hepes,
5 μg/mL Gentamycin, 10 U/mL Penicillin and 10 U/mL
Streptomycin (all from Lonza, Cologne, Germany), at
37°C, in a humidified 5% CO2 incubator.
Buffy coats were collected from HLA-A2+ and DR4+
healthy blood donors. Prior to blood draw, individuals
gave their informed consent according to the regulations
approved by the 2nd Peripheral Blood Transfusion Unit
and Haemophilia Centre, ‘Laikon’ General Hospital Insti-
tutional Review Board, Athens, Greece. PBMCs were iso-
lated by centrifugation over Ficoll-Histopaque (Lonza)
density gradient, resuspended in X-VIVO 15 (Lonza) or
cryopreserved in FBS-10% DMSO (Sigma-Aldrich Chem-
ical Co., St Louis, MO, USA) for later use.
DC maturation and T cell stimulation
Highly enriched monocytes (>80% CD14+) were obtained
from PBMCs by plastic adherence for 2 h at 37°C [65].
Non-adherent cells were removed and cryopreserved.
Monocytes were cultured for 5 days in X-VIVO 15
supplemented with 800 IU/mL recombinant human
granulocyte macrophage colony-stimulating factor (GM-
CSF) and 500 IU/mL recombinant human IL-4 (both from
R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany).
On day 5, iDCs were treated with LPS (0.5 μg/mL;
Sigma-Aldrich), TNF-α (10 ng/mL; R&D Systems),
proTα (160 ng/mL) or proΤα(100–109) (25 ng/mL) for
1–48 h, concentrations already reported to induce DC
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time points for phenotypic and TLR-4 analysis by flow
cytometry and immunoblotting, or were used to stimu-
late autologous T cells. Supernatants from 48 h ma-
tured DCs were also collected and the concentrations
of TNF-α, IL-10 and IL-12 were quantified using com-
mercially available ELISA kits (all from Life Technologies
Corporation, Carlsbad, USA), according to manufacturer’s
instructions. For TLR-4 neutralization experiments,
iDCs were pre-incubated in the presence of anti-TLR-4
(a-TLR-4) neutralizing monoclonal antibody (mAb;
clone W7C11) or an irrelevant mouse IgG1 mAb (both
from InvivoGen, San Diego, USA) at a final concentra-
tion of 10 μg/mL for 1 h and further stimulated with
LPS, proTα or proTα(100–109) for 48 h. TNF-α, IL-10
and IL-12 were determined in culture supernatants.
For T cell stimulation, 48 h matured DCs (1×106/mL)
were pulsed with 50 μg/mL HER-2(9369) and HER-2
(15776) for 6 h at 37°C, in a humidified 5% CO2 incuba-
tor in X-VIVO 15. DCs were washed twice, resuspended
in X-VIVO 15 and added to autologous lymphocytes
(non-adherent fraction) at a DC:lymphocyte ratio of
1:10. T cells were stimulated thrice at weekly intervals
and on days 3 and 5 after each stimulation, 40 IU/mL
IL-2 (Proleukin; Novartis Pharmaceuticals Ltd, UK) were
added to the cultures. At the third stimulation, Golgi-
Plug (1 μL/mL; Becton-Dickinson (BD) Biosciences,
Erembodegem, Belgium) was added in the cultures, and
12 h later, T cells were harvested and analyzed for cyto-
kine production by flow cytometry.
Flow cytometry analysis
For DC phenotype analysis, iDCs and mature DCs were
stained for the surface molecules HLA-DR, CD80,
CD83, CD86, CD11b, CD40 and CD14. Triple staining
was performed using appropriate combinations of FITC-,
PE- or PE-Cy5-labelled mouse anti-human IgG1 and IgG2
mAbs (BD Biosciences) at saturating concentrations for
30 min on ice. DCs were also stained with irrelevant anti-
human IgG1 and IgG2 mAbs (BD Biosciences), as isotype
controls. Samples were measured using a FACSCalibur
flow cytometer (BD Biosciences) and data were analyzed
using CellQuest software. MFI was evaluated for each
marker.
For TLR-4 expression, iDCs and DCs matured with
LPS, proTα or proTα(100–109) for 15 min, 30 min, 1 h,
18 h and 36 h were harvested and treated with human im-
munoglobulin (GAMUNEX; Bayer, Leverkusen, Germany)
and ethidium monoazide (EMA; Invitrogen, Karlsruhe,
Germany) to block Fc receptors and label nonviable cells,
respectively. DCs were then stained with TLR-4/Brilliant
Violet 421, CD11c/PE-Cy7 (both from BioLegend, San
Diego, CA) and Lineage 1 cocktail/FITC (BD Biosciences)
mAbs and measured immediately using LSR II orFACSCanto II and FACSDiva software (BD Biosciences).
Data were analyzed using FlowJo software (TreeStar,
Ashland, OR). Duplicates were excluded using the
forward-scatter area versus forward-scatter height plot,
TLR-4+ cells were gated within viable DCs (EMA-
negative (−), CD11c + and Lineage 1-) and their MFI was
determined. For TLR-4 neutralization experiments, a-
TLR-4-treated iDCs were stimulated as above and stained
with CD14/FITC (BioLegend) and TLR-4/Brilliant Violet
421 or PE (BioLegend) mAbs at saturating concentrations
for 30 min on ice. DCs were also stained with irrelevant
anti-human IgG2 mAbs (BD Biosciences), as isotype con-
trols. Samples were measured using a FACSCanto II and
data were analyzed using FACSDiva software.
For cytokine production analysis, T cells were harvested
and treated with GAMUNEX and EMA. They were
then stained with the following mAbs: CD3/eFluor 605,
IL-10/PE, and IL-17/PerCP-Cy5.5 (eBioscience, San
Diego, CA); CD-4/PerCP, CD-8/APC-H7, IL-4/APC, IFN-
γ/PE-Cy7 and CD107a/FITC (BD Biosciences); IL-2/
Alexa700 and TNF-α/Brilliant Violet 421 (BioLegend).
Samples were analysed immediately using an LSR II and
FACSDiva software and data were processed using FlowJo
software. Duplicates were excluded using the forward-
scatter area versus forward-scatter height plot, and CD4+
and CD8+ cells were gated within viable CD3+ lympho-
cytes and analyzed separately for cytokine production.
The percentage of cells producing each cytokine on gated
T cells was determined.
Cytotoxicity assay
The cytotoxic activity of thrice stimulated T cells was de-
termined by standard 51Cr- release assay. T2 cells were in-
cubated for 2 h at 37°C with 10 μg/mL HER-2(9369) or tyr
(9369), washed and labeled with sodium chromate, as pre-
viously described [21]. Non-loaded T2 were similarly
labeled for controls. Effectors (1×106/mL in X-VIVO 15;
100 μL/well) were seeded in 96-well U-bottom plates
(Greiner Bio-one, Kirchheim, Germany) and T2 targets
were added (5×104/mL; 100 μL/well), at an effector:target
(E:T) ratio of 10:1. Where indicated, mAb to MHC class I
molecules (W6/32, kindly donated by Prof. S. Stevanovic,
University of Tübingen) was added to the cultures at a
final concentration of 5 μg/mL for the entire incubation
period [66]. After 18 h of coincubation at 37°C, 5% CO2,
100 μL of supernatant were removed from each well and
isotope (counts per minute (cpm)) was counted in a γ-
counter (1275 Mini-gamma LKB Wallac, Turku, Finland).
To determine maximal and spontaneous isotope re-
lease, targets were incubated with 3 N HCl and in plain
medium, respectively. All cultures were set in triplicate.
Percentage of specific cytotoxicity was calculated according
to the formula: [(cpm experimental-cpm spontaneous)/
(cpm maximal-cpm spontaneous)] ×100.
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Stimulated T cells were seeded in 96-well U-bottom
plates (1 × 106/mL; 100 μL). Autologous matured DCs
pulsed with 50 μg/mL HER-2(15776) or tyr(15448) for 6
h, were added (1 × 105/mL; 100 μL/well) and cocultured
for 5 days. T cells incubated with unpulsed matured DCs
or in the presence of IL-2 (500 IU/mL) were used as
controls. Where indicated, mAb to MHC class II mole-
cules (L243, kindly donated by Prof. S. Stevanovic) was
added to the cultures at a concentration of 5 μg/mL for
the entire culture period [66]. For the last 18 h of cul-
ture, 1 μCi 3H-thymidine (Amersham Pharmacia Bio-
tech, Amersham, Bucks, UK) was added per well and
cells were harvested in a semi-automatic cell harvester
(Skatron Inc., Tranby, Norway). The amount of incorpo-
rated radioactivity, proportional to DNA synthesis, was
measured in a liquid scintillation counter (Wallac,
Turku, Finland) and expressed as cpm. The S.I. of each
experimental group was calculated using the formula:
(average cpm of sample in the presence of peptide-
pulsed DCs)/(average cpm of sample in the presence of
unpulsed DCs).Immunoblotting
Total cell extracts from 4–5×105 iDCs and DCs matured
with LPS, proTα or proTα(100–109) were extracted as de-
scribed [67]. Briefly, cells were lysed in NP-40 lysis buffer
(1% NP-40, 150 mM NaCl, 50 mM Tris pH 8.0)
containing protease inhibitors (Protease Inhibitor Cocktail,
Sigma-Aldrich) and lysates were cleared by centrifugation
for 10 min at 19,000 g (4°C). The protein content of ex-
tracts was determined by the Bradford assay, samples
were mixed with reducing Laemmli buffer and equal
protein amounts (15–25 μg) were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis using
12% (w/v) polyacrylamide gels. Separated proteins were
blotted on nitrocellulose membranes and probed with pri-
mary antibodies (goat anti-human ΤRIF/Novus Biologi-
cals, Ltd, Cambridge, UK; rabbit anti-human MyD88 and
rabbit anti-human TIRAP/eBioscience; rabbit anti-human
GAPDH/Santa Cruz Biotechnology Inc, Santa Cruz, CA,
USA) and horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (anti-rabbit-IgG and anti-goat-IgG/
Santa Cruz Biotechnology). Immunoblots were developed
using an enhanced chemiluminescence reagent kit (Santa
Cruz Biotechnology) and quantified by scanning densi-
tometry (Gel Analyzer v.1.0, Biosure, Athens, Greece).Statistical analysis
Data were analyzed by the Student’s t-test and statis-
tical significance was presumed at significance level of
5% (p < 0.05).Additional files
Additional file 1: Table S1. Range of % cytokine positive CD4+ and
CD8+ T cells. (A) Intracellular production of IFN-γ, TNF-α, IL-2, IL-4, IL-10
and IL-17 in, and expression of CD107 on CD4+ and CD8+ T cells
stimulated with DCs matured with TNF-α, proTα or proTα(100–109), in
the absence (−) or presence (+) of the HER-2/neu peptides. IL-5+ and
IL-13+ CD8+ T cells are additionally shown. Numbers indicate
percentages of positive cells. Shown is the range detected from 3–5
different donors tested. (B) Ratios of IFN-γ/IL-5 and IFN-γ/IL-13 in CD8+ T cells.
Shown is the range from 3 different donors tested.
Additional file 2: Figure S1. Kinetics of CD14 and TLR-4 surface
expression on monocytes, macrophages and iDCs/DCs upon stimulation
with LPS, proTα or proTα(100–109). Monocytes, macrophages and iDCs
(0 h) were stimulated with LPS (A), proTα (B), or proTα(100–109) (C) for
15 min, 30 min, 1 h and 18 h and assessed for the surface expression of
CD14 and TLR-4 using flow cytometry. MFI values in the presence of
neutralizing anti-TLR-4 Ab (+ a-TLR-4) are shown below each histogram.
Histograms are from one representative donor of 3 tested. Using the loss
of cell surface expression as a readout for TLR-4 and CD14 endocytosis
from 0–36 h [31], data from all three donors are shown as mean values ± SDs
for TLR-4 (D, E, F) and CD14 (G, H, I).
Additional file 3: Figure S2. CD14, TLR-4 and CD206 expression on
monocytes, monocyte-derived macrophages and monocyte-derived iDCs.
Macrophages were generated from human monocytes upon incubation
with 100 ng/mL GM-CSF for 5 days. Human monocytes were isolated
and iDCs were generated as described in Methods. Monocytes,
macrophages and iDCs were assessed for the surface expression of CD14,
TLR-4 and CD206 (as a specific marker for macrophages and DCs), using
flow cytometry. Histograms are from one representative donor of 3
tested and numbers indicate MFIs.Abbreviations
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